

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 24, 2026

Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader

RRID:SCR_019765

Type: Tool

Proper Citation

Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader
(RRID:SCR_019765)

Resource Information

URL: <https://www.biotek.com/products/detection-multi-mode-microplate-readers/synergy-neo2-hybrid-multi-mode-reader/>

Proper Citation: Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader
(RRID:SCR_019765)

Description: Microplate reader that is designed for a screening laboratory and combines variable bandwidth quad monochromators, sensitive high transmission filter-based optics, laser TRF and up to 4 PMTs to provide fast measurements.

Resource Type: instrument resource

Keywords: Biotek, BioTek, Multi-Mode Microplate Reader, Instrument Equipment, USEDit,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019765.pdf

Resource Name: Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader

Resource ID: SCR_019765

Alternate IDs: Model_Number_Synergy Neo2

Record Creation Time: 20220129T080346+0000

Record Last Update: 20260815T182626+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader.

No alerts have been found for Agilent: BioTek: Synergy Neo2 Hybrid Multi-Mode Microplate Reader.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Li J, et al. (2026) FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Cancer research, 86(2), 349.

Wang K, et al. (2026) Discovery of Bistratamides as Efficacious Reversers of P-Glycoprotein-Mediated Multidrug Resistance. Chemistry & biodiversity, 23(5), e71317.

Stitzlein LM, et al. (2025) Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma. Neuro-oncology advances, 7(1), vdaf246.

Braga Emidio N, et al. (2024) Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology. Molecular pharmacology, 105(3), 260.